Ikena Oncology’s (IKNA) “Neutral” Rating Reaffirmed at Wedbush

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “neutral” rating reaffirmed by investment analysts at Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They presently have a $2.00 price objective on the stock. Wedbush’s price target points to a potential upside of 19.76% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Ikena Oncology in a research note on Monday, November 11th.

Ikena Oncology Stock Performance

IKNA traded up $0.12 during trading on Monday, hitting $1.67. 5,144,815 shares of the stock were exchanged, compared to its average volume of 250,165. The firm has a 50 day simple moving average of $1.69 and a 200 day simple moving average of $1.69. The firm has a market cap of $80.59 million, a price-to-earnings ratio of -1.36 and a beta of 0.49. Ikena Oncology has a 1 year low of $1.22 and a 1 year high of $2.29.

Ikena Oncology (NASDAQ:IKNA) last issued its earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. As a group, equities analysts anticipate that Ikena Oncology will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ikena Oncology

A number of hedge funds have recently made changes to their positions in IKNA. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Ikena Oncology in the second quarter worth about $30,000. BBR Partners LLC acquired a new stake in Ikena Oncology in the 2nd quarter valued at about $33,000. AQR Capital Management LLC purchased a new position in Ikena Oncology in the 2nd quarter worth approximately $36,000. FMR LLC boosted its holdings in shares of Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock worth $66,000 after purchasing an additional 18,607 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ikena Oncology in the second quarter valued at approximately $75,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.